In the present research work codrugs of Propranolol and Metoprolol with Metformin were synthesized with an aim of improving the biological activity and to check the effectiveness of release of the parent drugs in presence of spacer. Ester prodrugs of Propranolol and metoprolol were synthesized by using succinic, maleic, pthalic anhydride and substituted derivatives of them. The resulted prodrugs were converted into codrugs (CO1-6) by reacting with Metformin. The compounds were characterized by melting point, FT-IR, 1 H-NMR and mass spectroscopy. The chemical hydrolysis of CO1-6 was carried out at the pH 1.2, 6.8 and 7.4. Almost all compounds showed encouraging chemical stability at pH 1.2 and 6.8 whereas showed the moderate hydrolysis at pH 7.4 but codrug CO4 didn't showed hydrolysis at any pH condition. Further codrugs were screened for antihypertensive and antidiabetic activity by simultaneous induction of two-kidney, one clip renal hypertension and STZ-induced diabetic model in wistar rats. The spacer containing dipropyl maleate codrugs (CO3 and CO6) showed longer duration of action. The current paper also describes about the molecular properties evaluation of the synthesized codrugs.
INDRODUCTION
eta blockers (Propranolol and Metoprolol) are mainly used in the treatment of heart disease and related conditions. These drugs reduce blood pressure and manage cardiac arrhythmias and are cardioprotective after myocardial infarction (heart attack) 1 . Beta-1 receptors are present in the kidneys, where they control the release of the hormone renin, which increases blood pressure, so beta-1 blockade of kidney receptors reduces blood pressure 2 . Over decades of clinical use, beta blockers have demonstrated good safety in patients of all ages. A major problem associated with Propranolol and Metoprolol is their high first passes metabolism and consequent poor systemic availability following oral administration.
The antidiabetic drug Metformin, biguinidine class drug is the choice of drug for patients with obesity and/or hyperlipidemic NIDDM. Along with antidiabetic effect Metformin also possesses good effects on dyslipidemia, hypertension, vascular function and fibrinolytic activity which are absolutely advantageous to patients with NIDDM, the major risk factor group of atherosclerosis or cardiovascular diseases. However Metformin has some drawbacks associated with it such as incomplete absorption from the upper intestine, rapid kidney excretion and suffers from low bioavilabilty and some side effects associated with gastrointestinal tract 3-6. ISSN: 2320-4850
[37] CODEN (USA): AJPRHS because they can reduce cardiovascular morbidity and mortality in persons with atherosclerotic cardiac disease. Diabetes and high blood pressure are strongly associated diseases. They occur together so frequently that they are officially considered to be "comorbidities". Coexistence of diabetes and hypertension in human is linked with cardiovascular risk and mortality 7-8. Various diseases are treated by a combination of therapeutic agents that are co-administered in separate dosage forms. However, there are potential advantages in delivering the co-administered agents as a single chemical entity. For example, improved delivery and pharmacokinetic properties compared to a physical mixture of the two drugs, and improved targeting of the drugs to site of action 9 .
The designing of prodrug has given the success to overcome the undesirable properties associated with the existing drug. Codrug concept is one step ahead as it minimizes the side effects along with increase in activity. Codrug consists of two pharmacologically active agents coupled together so that each can act as a promoiety for the other agent and vice versa. It is an important area of research, and its introduction in human therapy has given successful results in improving the clinical and therapeutic effectiveness of drugs suffering from some undesirable effects that otherwise hinder their clinical applications 10 .
The purpose of designing the codrugs of propranolol and Metoprolol with Metformin is to conquer the limitations like high first pass metabolism, slow and incomplete absorption from GIT which causes abdominal discomfort and pain, nausea, vomiting, diarrhea, anorexia, and metallic taste. In this regard the codrug molecules were specifically designed to determine if such codrugs could improve pharmacotherapy for both hypertension and diabetes, by providing a single, therapeutically effective, codrug dosage form to treat co-morbid conditions of hypertension and diabetes.
MATERIALS AND METHODS:
Propranolol and Metoprolol was obtained as gift samples from Cadila Healthcare Limited, Ahmadabad (India). All solvents were of analytical grade and distilled before use. All the reactions were carried out with dry, freshly distilled solvents under anhydrous conditions, unless otherwise noted. Melting points were determined by open capillary tubes and were uncorrected. FTIR spectra of the powdered compounds were recorded using ATR on a Bruker FTIR spectrophotometer and are reported in cm -1 and 1 H NMR spectra were recorded on a Bruker (400 MHz NMR) spectrophotometer using TMS as an internal reference (Chemical shift represented in δ ppm). Mass spectra were recorded on GC-MS QP5050A System (benchtop quadrupole mass spectrophotometer). Purity of the compound was checked on TLC plates using silica gel G as stationary phase and was visualized using iodine vapors or under UV chambers. In silico studies were carried out by using Accelrys drug discovery studio.
Synthetic studies
Propranolol prodrugs and codrugs were prepared according to the method described by Andhale GS et al., 2018 11 and Metoprolol prodrugs and codrugs were prepared according to the method described by Andhale GS et al., 2018 
Where, X= substituent"s used at in the synthesis showed as follows.
Physicochemical and spectral characterization of (CO1-6) 
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1-(isopropylamino)-3-(naphthalen-1-yloxy)propan-2-yl-2-((N'-(N,N-dimethylcarb amimidoyl) carbamimidoyl)carbamoyl)benzoate (CO4):
Yield: 68%; mp 189°C. FTIR (KBr) cm -1 : 3361.63 (N-H stre.), 2972.80 (Ar C-H stre.), 2886.59 (Ali C-H stre.), 1684.62 (C=O stre.), 1615.32, 1465.08 (Ar C=C stre.), 1292.01 (C-O-C stre.), 1118.10 (C-N). 1 
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Chemical hydrolysis studies:
Hydrolytic behavior of synthesized co-drugs was studied in Simulated Gastric Fluid (pH 1.2); Simulated Intestinal Fluid (pH 6.8); Simulated Plasma Fluid (pH 7.4). Chemical hydrolysis studies was carried out with USP-II paddle apparatus at a rotational speed of 50 rpm, temperature of 37±1°C, 900 ml solution of pH 1.2, 6.8 and 7.4 were used as dissolution media. 1 ml of the hydrolysis medium was taken out at 0 minute and every 15 min. for 120 min. 1 ml of the pH solution was added to the dissolution vessel [13] [14] . The sample withdrawn was analyzed with the HPLC using Phenomenex Luna C 18 column (250 mm x 4.6 mm id, 5 µm particle size), LC solutions software and mobile phase acetonitrile: water 70:30. Flow rate of mobile phase was kept at 1 mL/min at pressure 120-135 psi and UV detector (SPD-20A with D 2 lamp) was used and retention time and peak area were noted at 226 nm. The comparative study of rate of hydrolysis is shown as follows.
In-silico Evaluation of Physicochemical Properties:
The theoretical study of oral biodisponibility (Lipinski rule-of five) was performed in the Accelrys drug discovery studio. The theoretical oral bioavailability ranking of chemical compounds can be estimated using the Lipinski"s "rule-of-five", since it describes molecular properties important for a drug pharmacokinetics in the human body, including their absorption, distribution, metabolism and excretion (ADME). The active compound must present at least three of four rules: H-bond donors (HBD) ≤ 5, H-bond acceptors (HDA) ≤ 10, molecular mass (MM) ≤ 500, and the calculated logP (clogP) ≤ 5 [15] [16] [17] [18] .
Pharmacology:
All the experimental procedures and protocols used in this study were reviewed and approved by the 
(DM + HTN-MM) Antihypertensive Activity
The blood pressure (BP) was determined with a BIOPAC student, Inc, Tail-cuff method. The restrainer carrying the rat was placed in the BP instrument with tail stand out. The tail was lightly placed in touch with a transducer membrane, which was attached to the digital BP display panel. The instrument was then turned on and allowed to stabilize until steady pulse rate was observed. Then the BP recording button was pressed and the Systolic Blood Pressure was recorded. The test compounds were administered by oral feeding using an oral feeding needle [16] [17] [18] . Test compounds (codrugs) were prepared in 0.5% carboxymethyl cellulose (CMC) and dose of 20 mg/kg orally. Prior to dosing the animals, initial graph reading were taken to record the BP. Average readings were calculated by employing ANOVA method.
Antidiabetic Activity
Blood was withdrawn each time from the retro orbital plexus of the eye using capillary tube each time. The blood glucose levels of the animals in each group were checked at 0, 2, 4, 6, 8 and 10 h intervals study using glucometer 17 (Accu-check® active, Germany).
RESULTS AND DISCUSSION
Chemistry
Codrugs of Propranolol and Metoprolol with Metformin were prepared with an intend to enhance the bioavailability of parent drugs and thereby increasing 
through the absence of COOH peak of prodrug and the new peak was observed for C(O)NH in the spectra of all the codrugs.
In the FTIR spectra of all co-drugs, O-H peak of COOH was found to be absent which suggested the formation of co-drugs. FTIR data also shown the lower range of C=O peak of amide which also suggests the formation of co-drugs (CO1-6). The 1 H NMR spectrum also supports the scheme of synthesis by the absence of -COOH functional group indicating that it was involved in the reaction. New singlet peak was observed at δ 8.162 -8.263 ppm which corresponds for the NH of amide group, this confirms the formation of co-drugs, (CO1-6) of Propranolol and Metoprolol with Metformin by using various linkers of anhydrides.
Synthesized compounds have shown the respective M + peak for CO1, CO2, CO5, CO6, M + + 1 peak for CO3 and CO4 compound.
In-silico physicochemical properties evaluation:
The various codrugs (CO1-6) were submitted to an in silico evaluation using a molecular modeling approach. Since a good absorption after oral administration is obligatory for antihypertensive and antidiabetic activity purpose, we analyzed these compounds according to the rule-of five developed by Lipinski et al. (Table1) . The rule-of-five theoretically indicates if a chemical compound could be an orally active drug in humans. The rule states that the most "druglike" molecules present clogP ≤ 5, molecular weight (MW) ≤ 500, and number of hydrogen bond acceptors ≤ 10 and donors ≤ 5. Molecules violating more than one of these rules may have problems with bioavailability. The results showed that all codrugs (CO1-6) (Table1) fulfilled the Lipinski "rule-of-five" as violation of one rule is acceptable. Figure: 2. The hydrolysis rate of codrugs (CO1-6) at pH 1.2, 6.8 and 7.4.
Pharmacological evaluation
The parent drugs Propranolol, Metoprolol and Metformin have been used as a reference substance. All the synthesized codrugs (CO1-6) were screened for their antihypertensive and antihyperglycemic activity by simultaneous induction of two-kidney, one clip renal hypertension and STZ-induced diabetic model in wistar rats.
Antihypertensive activity
The Antihypertensive activity was determined by using Non invasive tail cuff method. After oral administration of standard drugs mixture (20 mg/kg) and synthesized codrugs (20 mg/kg) in rats, the blood pressure was determined from 0 to 12 h. The result showed that all the tested codrugs reduces the blood pressure significantly in comparison with the standard drug Propranolol and Metoprolol. Results of change in blood pressure in experimental study were presented in of this series showed longer duration of action but codrug (CO4) showed action after long period of time i.e after 900 minutes. In the series of MetoprololMetformin codrugs, CO5 showed the faster onset of action compared to that of standard drug Metoprolol. All other codrugs showed almost similar onset of action but duration of action is more when compared to standard drug Metoprolol. 4 and having the longer duration of action. The codrugs containing phthalate as a linker get hydrolyzed in a very negligible amount hence cannot get converted in to the parent drugs and it also didn"t displayed any pharmacological activity, so phthalate act as the very poor linkers in the codrug design. It was found that more the number of carbons in the linkage, chemical hydrolysis was slow and if the numbers of carbons are less in the linkage chemical hydrolysis were faster. Hydrolysis pattern of the best codrug indicate the release of the active drugs for longer period of time at pH 7.4 and no hydrolysis at pH 1.2 and 6.8. pH specific hydrolysis and slower hydrolysis of certain codrugs indicates the ratecontrolled and time controlled drug delivery of the actives.
